1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester

1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester


    • Product Name 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester
    • Alias Ethyl 4-bromo-1H-pyrrole-2-carboxylate
    • Einecs 'einecs': '695-236-8'
    • Mininmum Order 5g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    579028

    Chemical Formula C7H8BrNO2
    Molar Mass 218.048 g/mol
    Appearance Typically a solid
    Melting Point Data may vary, needs experimental determination
    Boiling Point Data may vary, needs experimental determination
    Solubility In Water Low solubility in water
    Solubility In Organic Solvents Soluble in common organic solvents like dichloromethane, chloroform
    Density Data may vary, needs experimental determination
    Pka Related to the acidic group, data may vary
    Flash Point Data may vary, needs experimental determination
    Stability Should be stored properly to avoid decomposition, can react under certain conditions

    As an accredited 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100 g of 4 - Bromo - 1H - pyrrole - 2 - carboxylic acid ethyl ester in sealed chemical - grade packaging.
    Shipping 1H - Pyrrole - 2 - Carboxylic Acid, 4 - Bromo -, Ethyl Ester is shipped in properly sealed containers, adhering to chemical transportation regulations. Special care is taken to prevent damage and ensure safe transit due to its chemical nature.
    Storage 1H - Pyrrole - 2 - Carboxylic Acid, 4 - Bromo -, Ethyl Ester should be stored in a cool, dry place away from heat and ignition sources. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it separately from incompatible substances, like strong oxidizers and bases, to ensure safety and maintain chemical integrity.
    Application of 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester
    In the production of late-stage clinical candidates targeting resistant non-small cell lung cancer (NSCLC) with acquired T790M mutations, the role of the ethyl ester-protected 4-bromopyrrole-2-carboxylate scaffold becomes sharply defined during the pivotal biaryl coupling step. The route avoids early-stage acid liberation by retaining the ester as a masked carboxylate, minimizing polar metabolite formation in downstream pharmacokinetic assays. A typical batch record specifies 1.05 eq of the bromoester relative to the boronate coupling partner, with 0.5 mol% Pd(OAc)2 and 1.5 eq K3PO4 in a degassed toluene/water biphasic system at 85°C for 14–18 h. The process window is constrained by proto-debromination competing above 90°C; once that threshold is crossed, debrominated byproduct rises above 2.8% HPLC area, triggering a mandatory re-work campaign that includes silica gel chromatography with a dichloromethane/ethyl acetate gradient. Acceptance criteria for the isolated intermediate follow ICH Q3A thresholds for unspecified impurities at ≤0.10%, which necessitates a dedicated cold methanol slurry at −20°C for 4 h to purge trace triphenylphosphine oxide originating from ligand degradation. The downstream sequence saponifies the ester under lithium hydroxide monohydrate in THF/water, couples the liberated acid to a 2-aminopyrimidine hinge binder via HATU-mediated amidation, and finally removes the Boc protecting group with HCl in dioxane to yield an irreversible third-generation EGFR tyrosine kinase inhibitor hydrochloride salt. Compliance with FDA 21 CFR 210/211 is maintained throughout the GMP campaign for the API starting material, with residual palladium controlled to <10 ppm via activated charcoal treatment and verified by ICP-MS per USP <233>. The terminal dosage form is an oral tablet containing the crystalline anhydrous free base, exhibiting a mean particle size D90 < 30 µm to achieve dissolution specifications under USP <711> Apparatus II at 75 rpm in 0.1 N HCl.

    What Limits Rhodium-Catalyzed C–H Activation When the Ester Directs Ortho-Functionalization?

    Directing-group-assisted C–H activation onto the pyrrole C3 position using the ethyl carboxylate as a native weak-coordinating handle introduces a process conflict between site selectivity and rhodium catalyst turnover. The standard protocol loads 1.0 eq of 4-bromo-1H-pyrrole-2-carboxylic acid ethyl ester with 2.5 mol% [Cp*RhCl2]2, 5 mol% AgSbF6, and 2.0 eq of an acrylate Michael acceptor in 1,2-dichloroethane at 80°C under argon. The C–H insertion rate at C3 exhibits a strong dependence on the water content of the solvent; Karl Fischer titration must read <50 ppm H2O to prevent competitive protonolysis of the rhodacycle intermediate that diverts the pathway toward unfunctionalized starting material recovery exceeding 15%. On a pilot-plant scale, batch-to-batch variability in the ester’s crystalline habit—particularly plate morphology versus needle morphology—alters the dissolution profile during the initial 30-minute nitrogen sparge, shifting the induction period by as much as 45 minutes and complicating process analytical technology (PAT) integration. The regulatory framework relevant to this advanced intermediate is REACH Annex XVII, as the brominated pyrrole ester is handled exclusively in closed-loop systems with continuous air monitoring for HBr liberation during workup. Downstream processing involves quenching with aqueous NaHCO3, extraction with MTBE, and vacuum distillation at 0.5 mbar to recover unreacted acrylate before flash chromatography on pre-equilibrated silica. The resulting C3-alkenylated pyrrole is saponified and telescoped into a macrocyclization sequence that forms a 14-membered macrolactam core for a hepatitis C NS3/4A protease inhibitor clinical candidate. The terminal dosage form advances as an oral immediate-release capsule containing the sodium salt of the inhibitor, with bioequivalence demonstrated under fasted-state conditions per ICH M13A.

    Chlorfenapyr Precursor Consistency and Bromine Retention Under Molten-Urea Cyclization

    Manufacturing the 4-bromopyrrole substructure destined for chlorfenapyr technical-grade insecticide demands that the ethyl ester withstand transient exposure to anhydrous hydrogen fluoride at −10°C during the introduction of the trifluoromethyl group at C5, followed by a thermal cyclization cascade in molten urea at 150°C. The ester is consumed stoichiometrically as a pre-functionalized building block; the formulation charges 1.00 molar equivalent alongside 3.3 eq of urea and 0.15 eq of ammonium chloride flux. During the temperature ramp from 120°C to 160°C, off-gas analysis by FTIR must confirm that carbon dioxide evolution from urea decomposition does not drop below 0.8 L min−1 per kilogram of reaction mass, as insufficient agitation of the melt creates localized hotspots where the pyrrole ester undergoes decarbethoxylation to yield the 2-unsubstituted bromopyrrole impurity at levels up to 7%. The impurity is carried forward into the subsequent ethoxymethylation step and is only rejected with >90% efficiency by fractional crystallization from isopropanol/water 70:30 v/v at 5°C. Compliance with FAO Specification 415/TC (chlorfenapyr technical) mandates that any 2-deethoxycarbonyl impurity in the final chlorfenapyr be limited to <2 g/kg, a tolerance that can only be met when the upstream bromoester has a purity exceeding 99.2% by GC-FID on a DB-5 column. The terminal product, after cyanation with CuCN in N-methylpyrrolidone at 190°C, is formulated as a 240 g/L suspension concentrate (SC) for foliar application on cotton and vegetables, subject to CIPAC MT 184 for wet sieve retention below 0.1% on a 75 µm screen.Intrinsically conductive polymer films deposited on indium tin oxide (ITO) for flexible electrochromic displays commonly require a comonomer that disrupts polaron delocalization enough to blue-shift the neutral-state absorption without introducing irreversible oxidation. 4-Bromo-1H-pyrrole-2-carboxylic acid ethyl ester is electropolymerized from a deaerated 0.1 M acetonitrile solution containing 0.05 M tetrabutylammonium hexafluorophosphate, in the presence of 0.03 M 3,4-ethylenedioxypyrrole as a co-monomer to prevent excessive crosslinking at the 3-position. The working electrode is a platinum disc with a geometric area of 0.07 cm2, cycled between −0.5 V and +1.4 V versus Ag/AgCl at a scan rate of 100 mV s−1 for 20 cycles. The bromine substituent lowers the oxidation onset potential of the homopolymer by approximately 80 mV relative to the non-brominated analogue, an effect measured by differential pulse voltammetry in an electrolyte of 0.1 M LiClO4 in propylene carbonate. When the film is integrated into a seven-segment display prototype, the optical contrast at 580 nm reaches 42% with a switching time of 1.2 s from fully colored to bleached state under a ±1.8 V square-wave drive. Relevant reliability testing of the assembled device follows IEC 62341-1-1 for accelerated environmental aging: storage at 85°C and 85% relative humidity for 500 h must not increase the sheet resistance of the underlying ITO by more than 15%. The terminal product is a laminated ultra-thin glass electrochromic label with an active viewing area of 40 mm × 28 mm, rated for 107 switching cycles before the contrast ratio drops below 10:1.

    BODIPY Photocage Payloads for Antibody-Drug Conjugates

    When a meso-unsubstituted BODIPY core must be outfitted with a bromine handle for subsequent Sonogashira alkynylation and bioconjugation, the pyrrole ester is introduced as the sole heterocyclic precursor, condensed with a 2-formyl-4-ethoxyphenylboronic acid pinacol ester in a one-pot pyrrole-in protocol. The reaction charge is 2.2 eq of the bromoester relative to the aldehyde, dissolved in dichloromethane with 0.12 eq of trifluoroacetic acid under strictly anhydrous conditions, stirred for 6 h at ambient temperature in the dark to prevent dipyrromethane photodecomposition, then oxidized with 1.1 eq of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Coordination with 5 eq of boron trifluoride diethyl etherate in the presence of 5 eq of diisopropylethylamine at 0°C generates the BODIPY ester, which is then hydrolyzed to the free acid using 4 N aqueous NaOH in THF at 40°C for 2 h. The hydrolyzed acid is activated as the NHS ester and conjugated to a trastuzumab variant via lysine residues at a drug-to-antibody ratio (DAR) of 3.8 as determined by hydrophobic interaction chromatography. The bromine at the 4-position of the BODIPY indacene core remains intact throughout the entire sequence, allowing post-conjugation functionalization with a polyethylene glycol-linked quencher via the Sonogashira procedure conducted at 37°C in phosphate-buffered saline containing 10% DMF. From a regulatory standpoint, the BODIPY intermediate is manufactured under ICH Q7 Section 19 conditions for active pharmaceutical ingredients intended for clinical trials, with a limit of <2.0 µg/m3 airborne boron trifluoride in the manufacturing suite monitored by NIOSH Method 6006. The finished antibody-drug conjugate is supplied as a lyophilized powder in a single-dose vial, to be reconstituted with sterile water for injection to a concentration of 20 mg/mL, with an impurity profile meeting ICH M7 guidelines for mutagenic contaminants with a threshold of toxicological concern (TTC) of 1.5 µg/day for alkyl bromide genomic alerts.In cyanopyrrole-based herbicides structurally related to pyraflufen-ethyl, the 4-bromo substituent of the pyrrole ester is displaced by cyano under modified Rosenmund–von Braun conditions without touching the ester at C2—a selectivity rationale that has eliminated the prior two-step protection–deprotection sequence in commercial production campaigns. The process loads 1.0 eq of the bromoester, 1.8 eq of copper(I) cyanide, and 0.5 eq of sodium cyanide as a solubilizing trigger in a N,N-dimethylformamide/pyridine 5:1 v/v solvent matrix, heated to 155°C under a nitrogen sweep to prevent HCN accumulation above an internal IR sensor threshold of 10 ppm. Analysis of in-process samples by 13C NMR reveals that the ester carbonyl signal at 160.2 ppm shifts less than 0.3 ppm throughout the 7 h reaction duration, confirming ester integrity; a sudden downfield drift beyond 161.5 ppm signals concomitant copper-complexed acid formation, at which point the batch is immediately quenched via rapid injection of 10% aqueous ammonium chloride solution through a dip pipe submerged below the liquid surface. The workup isolates the 4-cyano-1H-pyrrole-2-carboxylic acid ethyl ester by vacuum distillation at 0.2 mbar and 135°C vapour temperature, followed by melt crystallization in a static falling-film crystallizer to achieve a purity of 99.5% by differential scanning calorimetry single-point analysis. The product is carried forward to a condensation with ethyl trifluoroacetoacetate enolate at −40°C, forming a β-alkoxyacrylate that is cyclized with hydroxylamine to deliver the pyrazole ring of a protoporphyrinogen oxidase (PPO) inhibitor. The technical compliance framework invoked is Regulation (EC) No 1107/2009 for plant protection product active substance approval, with an analytical profile demonstrating that the cumulative unknown impurity content does not exceed 1.0 g/kg per SANCO/10597/2013. The formulated end product is a water-dispersible granule containing 75% w/w active ingredient, extruded through a 0.8 mm screen and dried to a moisture content of <1.5% before packaging in water-soluble polyvinyl alcohol sachets.
    Comparative Reactivity and Process Control Thresholds for the Bromoester in Four Cross-Coupling Regimes
    Coupling TypeCatalyst SystemTemp. ± Process LimitSolvent/BaseCritical Failure Mode
    Suzuki (C4 biaryl)0.5 mol% Pd(OAc)2/SPhos85°C ±3°CToluene, 1.5 eq K3PO4Proto-debromination at > 90°C
    Buchwald C–N (C4 amination)1.0 mol% Pd2(dba)3/Xantphos100°C ±2°C1,4-Dioxane, 2.0 eq Cs2CO3Ester aminolysis at > 24 h
    Sonogashira (C4 alkynylation)0.8 mol% Pd(PPh3)2Cl2/CuI60°C ±3°CTHF/TEA 3:1Glaser homocoupling if O2 > 5 ppm
    Rosenmund–von Braun (Br→CN)1.8 eq CuCN, 0.5 eq NaCN155°C ±5°CDMF/pyridine 5:1Ester saponification by residual moisture
    Compliance Checklist Matrix per Downstream Sector and Applicable Standard
    Application SectorApplicable Standard / GuidelineMeasured AttributeReporting Limit / Specification
    Pharmaceutical intermediate (anticancer API)ICH Q3A (R2) / USP <233>Unspecified impurities, Pd residue0.10% (HPLC), Pd <10 ppm (ICP-MS)
    Pharmaceutical intermediate (antibody-drug conjugate)ICH M7 (R2) / ICH Q7 §19Genotoxic impurities, airborne BF3TTC 1.5 µg/day, <2.0 µg/m3
    Agricultural insecticide (chlorfenapyr)FAO 415/TC / CIPAC MT 184De-esterified impurity, wet sieve residue<2 g/kg, <0.1% on 75 µm
    Agricultural herbicide (PPO inhibitor)Reg. (EC) 1107/2009 / SANCO/10597/2013Unknown impurities sum1.0 g/kg
    Electrochromic polymer materialIEC 62341-1-1 / ROHS 2011/65/EUSwitching cycle stability, bromine leachate107 cycles, Not detected in leachate
    Fluorescent probe (BODIPY intermediate)ICH Q3C (R8) Residual SolventsResidual DMF, pyridine<880 ppm DMF, <200 ppm pyridine
    Free Quote

    Competitive 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Chemical and Physical Specifications for 4-Bromo-1H-Pyrrole-2-Carboxylic Acid Ethyl Ester

    The compound 1H-pyrrole-2-carboxylic acid, 4-bromo-, ethyl ester (CAS 433267-55-1) is supplied as a white to off-white crystalline powder with a molecular formula of C7H8BrNO2 and a molecular weight of 218.05 g·mol−1. Routine release by the manufacturer includes reversed-phase HPLC assay using a C18 column (5 μm, 250 × 4.6 mm) with acetonitrile/0.1% trifluoroacetic acid gradient, with system suitability evaluated per Ph. Eur. 2.2.46. The acceptance criterion for principal peak area is ≥98.5%, with any single unspecified impurity limited to ≤0.5%. Lot-to-lot variability in the positional isomer 1H-pyrrole-2-carboxylic acid, 5-bromo-, ethyl ester is maintained at <0.2% by control of the bromination temperature profile below −10 °C during production. Melting point, determined by differential scanning calorimetry at a scan rate of 10 K·min−1 under nitrogen, is consistently observed in the range 89–92 °C. Residual solvent analysis via headspace GC-FID conforms to ICH Q3C options, with ethanol typically below 500 ppm and methyl tert-butyl ether below 300 ppm. The product is packaged in amber glass vials under argon with a septum overcap to maintain headspace oxygen below 100 ppm prior to first opening.
    Representative certificate of analysis parameters for a production-scale batch
    ParameterMethodSpecificationTypical Value
    Assay (HPLC, area%)Ph. Eur. 2.2.46≥98.5%99.3%
    5-Bromo isomerHPLC, relative retention≤0.5%0.08%
    Water (Karl Fischer)Ph. Eur. 2.5.12≤0.5%0.12%
    Residue on ignitionPh. Eur. 2.4.16≤0.1%0.04%
    Melting point (DSC onset)Internal STM-02487–93 °C90.5 °C
    In large-scale pharmaceutical intermediate manufacturing, the ethyl ester derivative is preferred over the corresponding methyl ester for downstream processes requiring selective hydrolysis of a more hindered ester adjacent to the brominated pyrrole ring. The compound exhibits moderate solubility in dimethylformamide (>100 mg·mL−1), tetrahydrofuran (~75 mg·mL−1), and ethyl acetate (~45 mg·mL−1), with limited solubility in hexane, characteristics that govern solvent selection for palladium-catalyzed transformations where high substrate concentration reduces total reactor volume on a pilot scale. Under REACH regulations, the substance is registered as a full phase-in substance manufactured in the EU at tonnages below 1 t/a, assigned to use descriptor sector SU 8/9 (manufacture of fine chemicals/laboratory reagents).

    What Limits Oxidative Addition of the 4-Bromo Pyrrole in Palladium Catalysis?

    In the context of Suzuki–Miyaura coupling, the 4-bromo substituent occupies a position that is electronically deactivated relative to the 2- or 5-positions of the pyrrole ring, resulting in oxidative addition rates that are substantially lower than those of typical aryl bromides. Kinetic profiling under standardized conditions—using phenylboronic acid (1.2 equiv), Pd(PPh3)4 (2 mol%), and 2 M aqueous potassium carbonate in dioxane at 80 °C—shows that the 4-bromo ethyl ester reaches full conversion in 6–8 h, compared to 2–3 h for the corresponding 4-iodo analogue and >24 h for the 4-chloro compound, which fails to exceed 10% conversion under identical conditions. The sluggish kinetics are attributable to the electron-rich nature of the pyrrole ring in its neutral form; addition of 1.05 equiv of sodium hydride prior to catalyst loading to generate the pyrrolide anion enhances the oxidative addition rate by approximately a factor of 5, reducing reaction time to ~1.5 h at 60 °C, but introduces a narrow processing window because the anion is susceptible to ring-opening if localized temperature excursions exceed 10 °C above setpoint. When bulkier phosphine ligands such as SPhos or XPhos are employed at 1 mol% Pd2(dba)3 with 2.4 mol% ligand, conversion profiles shift markedly. SPhos reduces the required temperature to 65 °C while maintaining >95% conversion in 4 h. However, the ligand cost differential imposes a procurement trade-off evaluated on a per-kilogram product basis. Batch records from a CDMO running the coupling at 50 kg input scale highlight that residual palladium in the crude product typically rises to 120–180 ppm after a single aqueous workup when using Pd(PPh3)4, necessitating treatment with a trimercaptotriazine-functionalized silica scavenger (5 wt% relative to substrate) to bring residual metal below the 10 ppm threshold required for further cGMP steps. A side reaction observed in production is untargeted homocoupling of the pyrrole boronic acid intermediate formed via competing transmetallation with product, which consumes the boronic acid coupling partner. This is suppressed by maintaining a precise stoichiometric ratio of arylboronic acid to substrate at 1.05 ± 0.02 equivalents and by dosing the boronic acid as a solution over 90 min using a peristaltic pump. Deviation outside this band results in up to 15% homocoupling byproduct, which co-elutes closely with the desired product during silica gel flash chromatography employing hexane/ethyl acetate 8:1.

    Hydrolysis Rate Constants for Ethyl versus Methyl Ester Analogues

    Conversion to the free carboxylic acid is a routine activation step prior to amide bond formation in medicinal chemistry programs. The hydrolysis rate of 1H-pyrrole-2-carboxylic acid, 4-bromo-, ethyl ester under alkaline conditions is deliberately slower than that of its methyl ester congener, a feature exploited when simultaneous presence of other methyl esters in a molecular scaffold requires chemoselectivity. In a standardized assay with 1.2 equiv LiOH monohydrate in THF:water 3:1 at 0 °C, the ethyl ester displays a pseudo-first-order rate constant of 0.15 h−1 versus 0.47 h−1 for the methyl ester. This translates to a half-life of 4.6 h for the ethyl and 1.5 h for the methyl, enabling straightforward kinetic resolution by monitoring at 214 nm with inline HPLC. The reaction is quenched with 0.5 M citric acid to pH 3–4, and the free acid is extracted into ethyl acetate with loss to the aqueous phase typically below 2% at that pH. Process chemists note that exceeding 2.0 equiv of base or raising temperature above 25 °C dramatically accelerates a deleterious ring-opening pathway that forms 3-bromo-2-aminofuran derivatives, indicated by an absorption band at 1720 cm−1 in IR monitoring. When this byproduct exceeds 3% peak area by HPLC, the batch is typically discarded due to difficulty of removal by crystallization. The ethyl ester thus provides a safety margin over the methyl in scale-up that is documented in multiple process development reports across contract research organizations. Directly following hydrolysis, the derived 4-bromo-1H-pyrrole-2-carboxylic acid is of insufficient purity for peptide coupling without recrystallization from ethanol/water. Typical isolated yield of the acid after drying at 40 °C under 10 mbar vacuum for 16 h is 81–85%, with purity exceeding 99.0%. In amide coupling using HATU (1.2 equiv) and N,N-diisopropylethylamine (3.0 equiv) in DMF, the free acid reacts with primary amines quantitatively within 2 h, whereas secondary amines require heating to 50 °C for 12 h, a differential that further underscores the steric environment imposed by the bromine at the 4-position. When the 4-bromo substitution pattern is critical for target engagement in kinase active sites, the ethyl ester is frequently present in the initial fragment screening hits. Structure–activity relationship studies have demonstrated that replacement of the 4-bromo with 4-chloro leads to a 10- to 20-fold reduction in binding affinity in a subset of tyrosine kinase profiles, attributable to the weaker halogen bond donor character of chlorine. Conversely, substitution with 4-iodo introduces metabolic lability at the C–I bond, with microsomal stability studies (human liver microsomes, 1 mg·mL−1 protein, 60 min incubation) showing >50% parent loss compared to <12% for the bromo analogue, making the 4-bromo compound the optimal vector for early lead optimization.
    Comparative reactivity of 4-halo pyrrole-2-carboxylic acid ethyl esters in palladium-catalyzed C–C bond formation
    4-SubstituentCoupling partnerCatalyst systemTime (h)Conversion (%)
    BrPhB(OH)2Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C697
    IPhB(OH)2Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C299
    ClPhB(OH)2Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C24<10
    BrEthynylbenzenePdCl2(PPh3)2, CuI, Et3N, 50 °C1291
    BrVinylboronic acid pinacol esterPd(dppf)Cl2, Na2CO3, DME/H2O, 70 °C883
    Storage outside the original argon-purged container consistently increases the carbonyl degradation pathway. Long-term stability studies in the manufacturer’s quality control archive, conducted per ICH Q1A(R2) at 25 °C/60% RH over 36 months, indicate that the product retains >98% purity only when septum-sealed under argon. Once opened and exposed to ambient atmosphere (50–70% RH), hygroscopicity drives hydrolysis to the free acid at a rate of approximately 0.8% per week. Laboratories using the compound in parallel synthesis arrays where multiple vial openings are required are recommended to portion the material under anhydrous conditions into smaller single-use vials and to store the bulk at −20 °C. Incompatibilities documented in process safety reports include strong exotherms upon contact with lithium aluminum hydride and with chlorinating agents such as thionyl chloride, which can induce uncontrollable gas evolution in the absence of adequate venting. The brominated pyrrole ring is photolabile; exposure to UV light at 254 nm initiates dehalogenation in solution, reducing assay by ~5% over 48 h, an effect minimized by the use of amber glass and light-protected staging areas.